First Tracks director exercises RSUs, adds 7,330 shares

First Tracks Biotherapeutics director Rita Jain exercised equity awards to acquire additional common shares.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

First Tracks Biotherapeutics director Rita Jain exercised equity awards to acquire additional common shares. On June 15, 2026, she acquired 7,330 shares of common stock through the exercise or conversion of restricted stock units at no cash exercise price, increasing her direct holdings to 19,194 shares.

The filing shows two RSU tranches of 1,300 and 6,030 units converting into common stock. Footnotes explain that each RSU represents a contingent right to receive one share upon settlement for no consideration, with vesting tied to continued service through June 15, 2026.

Insider Trade Summary

7,330 shares exercised/converted

Exercise 3 txns

Insider Jain Rita

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	6,030	$0.00	$0.00
Exercise	Restricted Stock Unit	1,300	$0.00	$0.00
Exercise	Common Stock	7,330	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 19,194 shares (Direct)

Footnotes (3)

F1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3. The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date.

Key Figures

Shares acquired via exercise: 7,330 shares Post-transaction holdings: 19,194 shares RSU tranche: 1,300 units +3 more

6 metrics

Shares acquired via exercise 7,330 shares Common Stock acquired on June 15, 2026 through derivative exercise

Post-transaction holdings 19,194 shares Common Stock directly held after June 15, 2026 transactions

RSU tranche 1,300 units Restricted Stock Units converting into 1,300 common shares

RSU tranche 6,030 units Restricted Stock Units converting into 6,030 common shares

Single-date vesting June 15, 2026 RSUs vest 100% on this date, subject to continued service

Installment vesting dates June 15, 2024/2025/2026 RSUs vest 33.33% on each listed date with service condition

Key Terms

Restricted Stock Unit, contingent right, Exercise or conversion of derivative security, vests as to 100% of the total RSUs, +1 more

5 terms

Restricted Stock Unit financial

"Each restricted stock award ("RSU") represents a contingent right to receive 1 share..."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"represents a contingent right to receive 1 share of the Issuer's Common Stock..."

Exercise or conversion of derivative security financial

"transaction_code_description":"Exercise or conversion of derivative security""

vests as to 100% of the total RSUs financial

"The RSUs vests as to 100% of the total RSUs on June 15, 2026..."

vests as to 33.33% of the total shares financial

"The RSUs shall vest as to 33.33% of the total shares on June 15, 2024..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did First Tracks Biotherapeutics (TRAX) report for Rita Jain?

Rita Jain reported exercising equity awards to acquire 7,330 shares of First Tracks Biotherapeutics common stock. These shares came from restricted stock units converting into stock, reflecting compensation-related activity rather than an open-market purchase or sale.

How many First Tracks Biotherapeutics shares does Rita Jain hold after this Form 4?

After the June 15, 2026 transactions, Rita Jain directly holds 19,194 shares of First Tracks Biotherapeutics common stock. This total reflects the 7,330 shares acquired through the exercise or conversion of restricted stock units disclosed in the Form 4.

What are the details of the RSUs in the First Tracks Biotherapeutics (TRAX) Form 4?

The Form 4 lists restricted stock units in tranches of 1,300 and 6,030 units, each convertible into one share of common stock. Footnotes state they settle for no consideration and vest based on continued service through specified dates, including June 15, 2026.

Were any First Tracks Biotherapeutics shares bought or sold on the market in this filing?

No open-market buys or sells are reported. The Form 4 shows derivative exercises labeled as “Exercise or conversion of derivative security,” where restricted stock units converted into 7,330 common shares at a stated price of $0.0000 per share.

How do the RSU vesting terms work for Rita Jain at First Tracks Biotherapeutics?

Footnotes explain some RSUs vest 100% on June 15, 2026, conditioned on continued service. Another grant vests in roughly three equal 33.33% installments on June 15, 2024, June 15, 2025, and June 15, 2026, also requiring ongoing service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/17/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Rita

(Last)

(First)

(Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		M		7,330	A	$0⁽¹⁾	19,194	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	06/15/2026		M			6,030	⁽²⁾	⁽²⁾	Common Stock	6,030	$0	0	D
Restricted Stock Unit	⁽¹⁾	06/15/2026		M			1,300	⁽³⁾	⁽³⁾	Common Stock	1,300	$0	0	D

Explanation of Responses:

1. Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The RSUs shall vest as to 33.33% of the total shares on June 15, 2024, and thereafter vests as to 33.33% of the total RSUs on June 15, 2025; and as to 33.33% of the total RSUs on June 15, 2026, subject to the provision of services to the Company on each vesting date.

	/s/ Ajim Tamboli, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR